<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03758222</url>
  </required_header>
  <id_info>
    <org_study_id>10-MSC-1164</org_study_id>
    <secondary_id>(PN7585, 7998), 10-MSC-1082</secondary_id>
    <nct_id>NCT03758222</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility of the XFLO Expander System (Mercury)</brief_title>
  <acronym>EXPANDER-1</acronym>
  <official_title>A Clinical Study to Evaluate the Safety and Feasibility (Including First in Human) of the XFLO EXPANDER SYSTEM (EXPANDER-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedeonBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedeonBio, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the safety and feasibility of the Mercury Expander system and procedure to&#xD;
      treat patients with lower urinary tract symptoms (LUTS) secondary to urinary outflow&#xD;
      obstruction from benign prostatic hyperplasia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, non-randomized, two-arm, multi-center clinical trial designed to evaluate the&#xD;
      safety and feasibility of the Mercury Expander system in patients with lower urinary tract&#xD;
      symptoms (LUTS) secondary to urinary outflow obstruction from benign prostatic hyperplasia&#xD;
      (BPH).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2018</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from Unanticipated adverse device effects (UADEs)</measure>
    <time_frame>1 month (Arm-1)</time_frame>
    <description>Measure any device or procedure related adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from Unanticipated adverse device effects (UADEs)</measure>
    <time_frame>6 months (Arm-2)</time_frame>
    <description>Measure any device or procedure related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from Unanticipated adverse device effects (UADEs)</measure>
    <time_frame>7 months (Arm-1)</time_frame>
    <description>Measure any device or procedure related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Unanticipated adverse device effects (UADEs)</measure>
    <time_frame>12 months (Arm-2)</time_frame>
    <description>Measure any device or procedure related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in International Prostate Symptom Score (IPSS)</measure>
    <time_frame>1 month and 7 months (Arm-1)</time_frame>
    <description>Measure improvement in lower urinary tract symptoms related to benign prostatic hyperplasia (BPH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in International Prostate Symptom Score (IPSS)</measure>
    <time_frame>6 and 12 months (Arm-2)</time_frame>
    <description>Measure improvement in lower urinary tract symptoms related to benign prostatic hyperplasia (BPH)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Arm-1: Device implantation for 1 month</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group receives intervention with the XFLO Expander System implantation for 1 month, and then retrieved.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm-2: Device implantation for 6 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group receives intervention with the XFLO Expander System implantation for 6 months, and then retrieved.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm-3: Device implantation for 12 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group receives intervention with the XFLO Expander System implantation for 12 months, and then retrieved.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XFLO Expander System</intervention_name>
    <description>Implantation and retrieval of the XFLO Expander System in the prostatic urethra to treat benign prostatic hyperplasia (BPH)</description>
    <arm_group_label>Arm-1: Device implantation for 1 month</arm_group_label>
    <arm_group_label>Arm-2: Device implantation for 6 months</arm_group_label>
    <arm_group_label>Arm-3: Device implantation for 12 months</arm_group_label>
    <other_name>Mercury</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male gender&#xD;
&#xD;
          -  Age ≥ 50 years&#xD;
&#xD;
          -  Prostate volume 30 - 80 cc by Abdominal Ultrasound (AUS) or Trans Rectal Ultrasound&#xD;
             (TRUS)&#xD;
&#xD;
          -  Prostatic urethra length of 2.0-6.0 cm, as measured from bladder neck to verumontanum,&#xD;
             using cystoscopy (or prostate length from bladder neck to external sphincter of&#xD;
             2.0-8.0 cm during screening visit, using ultrasound).&#xD;
&#xD;
          -  Medication history&#xD;
&#xD;
               -  Not on BPH related medication for the past 6 months.&#xD;
&#xD;
               -  If on BPH related medication:&#xD;
&#xD;
                    -  On 5-alpha-reductase inhibitors (ARIs), the patient must be on the&#xD;
                       medication for at least 3 months with a stable voiding pattern&#xD;
&#xD;
                    -  On alpha-blockers, the patient must be on the medication for at least 3&#xD;
                       weeks with a stable voiding pattern&#xD;
&#xD;
          -  Patients with symptomatic BPH and related lower urinary tract symptoms (LUTS):&#xD;
&#xD;
               -  With International Prostate Symptom Score (IPSS) &gt; 13; Qmax &lt; 12 mL/sec on a&#xD;
                  voided volume ≥125 mL; Post-void residual (PVR) &lt; 250 mL; QoL score ≥ 3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous BPH procedure&#xD;
&#xD;
          -  Median prostatic lobe or high bladder neck&#xD;
&#xD;
          -  Urethral stricture, meatal stenosis, or bladder neck obstruction - either current, or&#xD;
             recurrent requiring 2 or more dilatations&#xD;
&#xD;
          -  Elevated Prostate Specific Antigen (PSA) ≥ 10 ng/mL unless negative biopsy within last&#xD;
             6 months, or a positive biopsy showing cancer&#xD;
&#xD;
          -  Cystolithiasis within the prior 3 months&#xD;
&#xD;
          -  History of neurogenic bladder or urinary retention with PVR &gt;1000mL.&#xD;
&#xD;
          -  Serum creatinine &gt;1.8 mg/dl or upper-tract disease which compromises renal function&#xD;
&#xD;
          -  Current or recent Urinary Tract Infection (UTI) or disease&#xD;
&#xD;
          -  Known allergy to nickel&#xD;
&#xD;
          -  Life expectancy of less than 24 months&#xD;
&#xD;
          -  Known coagulopathies or subject on anticoagulants or antiplatelets other than aspirin&#xD;
             ≤ 100 mg (unless antiplatelets are withheld minimum 3 days prior to procedure)&#xD;
&#xD;
          -  Anticipated need for additional surgery or treatments for comorbidities during the&#xD;
             study period.&#xD;
&#xD;
          -  Current gross hematuria&#xD;
&#xD;
          -  Other co-morbidities that could impact the study results&#xD;
&#xD;
          -  Unable or unwilling to complete all required questionnaires and follow-up assessments&#xD;
&#xD;
          -  Unable or unwilling to sign informed consent form&#xD;
&#xD;
          -  Currently enrolled in any other investigational clinical research trial that has not&#xD;
             completed the primary endpoint.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Benign prostatic hyperplasia (BPH) is a male disease</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Woo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Australian Clinical Trials Pty Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joyce T. Su, MPH</last_name>
    <phone>6503975100</phone>
    <email>joyce.su@medeonbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Australian Clinical Trials Pty Ltd</name>
      <address>
        <city>Wahroonga</city>
        <state>New South Wales</state>
        <zip>2076</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry Woo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Henry Woo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iris Chan</last_name>
      <email>Iris.Chan2@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Dean Elterman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brunswick Medical Center</name>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Tisseur</last_name>
    </contact>
    <investigator>
      <last_name>Kevin Zorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Center of Urology</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi-Ping Huang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Georgia</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 26, 2018</study_first_submitted>
  <study_first_submitted_qc>November 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2018</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

